Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Postpartum Neurobiological Sequelae of Prescription Opioid Use During Pregnancy

Award Number: K99DA060209
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 05/30/2025

Group Awards By:

View Award Description

Postpartum Neurobiological Sequelae of Prescription Opioid Use During Pregnancy - PROJECT SUMMARY Pregnancy is a critical period for brain development, and drug use during this time disrupts ontogenic trajectories. During the last decade, the use of prescription opioids during pregnancy has reached notably high rates (14- 22%) in the United States. While previous research has focused on the offspring for in utero effects of opioid use, the impact on the mother’s postpartum mental health has been largely overlooked. Notably, drug overdoses are one of the main preventable causes of pregnancy-related deaths, mainly occurring in this period. Here, we will assess the neurobehavioral changes caused by prescription opioid exposure during pregnancy and their postpartum impact on drug reward. The proposed work will focus on two key at-risk mechanisms during pregnancy: oxytocin and dopamine. Central oxytocin signaling by paraventricular hypothalamic neurons (PVNOXT) is halted during pregnancy and quickly re-initiated after parturition. Upon resumption of oxytocin release, ventral tegmental area (VTA)-projecting PVNOXT neurons promote attribution of incentive value to salient stimuli (e.g., pups). Therefore, VTA-projecting PVNOXT, which express µ-opioid receptors (µOR), represent a substrate for the pharmacological actions of prescription opioids (such as oxycodone) during pregnancy. We hypothesize that repeated activation of PVNOXT µOR leads to opioid tolerance and a long-term loss of inhibitory control over PVNOXT excitability, hence exacerbating VTA oxytocin release and altering dopamine function postpartum. We will use drug self-administration and neuroeconomic modeling to profile postpartum vulnerability to drug abuse in dams exposed to prescription opioids during pregnancy. Additionally, we will employ fiber photometry to examine in vivo changes in dopamine and oxytocin encoding of opioid rewards and electrophysiological tools to characterize PVNOXT synaptic alterations. Finally, optogenetic manipulations will address the sufficiency of the PVNOXT→VTA pathway to gate augmented postpartum reward-seeking behaviors in opioid-naïve mice. Together, these experiments will uncover novel behavioral and neural circuit aberrations resulting from prescription opioid exposure during pregnancy, focusing on the dam’s vulnerability to postpartum opioid abuse. Ultimately, this research proposal seeks to uncover a potential neurobiological mechanism linking the increased use of prescription opioids during pregnancy and the rise in postpartum overdose deaths.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	2	1/21/2026	NON-COMPETING CONTINUATION	$0
2026	2025	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	2	2/11/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $191,608 )
2025	2025	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	2	1/15/2025	NON-COMPETING CONTINUATION	$191,608
														Subtotal = $191,608

Issue Date FY: 2024 ( Subtotal = $178,322 )
2024	2024	UNIVERSITY OF MARYLAND, BALTIMORE	220 ARCH ST OFC LEVEL2	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	1	2/28/2024	NEW	$178,322
														Subtotal = $178,322

Grand Total All Awards = $369,930

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Postpartum Neurobiological Sequelae of Prescription Opioid Use During Pregnancy

Award Number: K99DA060209

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 05/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer